Journal of Cardiovascular Pharmacology最新文献

{"title":"The Novelty of Anticoagulation in LVAD Therapy: Current Practice, the Role of Direct Oral Anticoagulants, and Future Directions.","authors":"Dor Lotan, Boaz Elad, Changhee Lee, Ilan Richter, Kevin Clerkin, Ersilia M DeFilippis, Afsana Rahman, Adil Yunis, Justin Fried, Jayant Raikhelkar, Koji Takeda, Gabriel Sayer, Nir Uriel","doi":"10.1097/FJC.0000000000001847","DOIUrl":"10.1097/FJC.0000000000001847","url":null,"abstract":"<p><strong>Abstract: </strong>Left Ventricular Assist Devices (LVADs) are an established therapy for end-stage heart failure as bridge-to-transplant and destination therapy. Despite advances with fully magnetically levitated devices such as the HeartMate 3, hemocompatibility-related adverse events, most notably bleeding, remain frequent, and drive morbidity and readmissions. Bleeding risk is multifactorial, reflecting anticoagulation, comorbidities, vascular abnormalities, and acquired hematologic disorders. We conducted a narrative review of thrombotic and bleeding outcomes associated with anticoagulation strategies in continuous-flow LVAD patients. From 417 screened records, 10 studies were included, focusing on direct oral anticoagulants. The 10 studies comprised 174 LVAD-supported patients treated with direct oral anticoagulants, primarily apixaban; most were on the HeartMate 3 (n = 146). Among factor Xa inhibitor studies, thrombotic event rates ranged from 0% to 12.5% and bleeding from 6% to 20%-broadly comparable with or lower than warfarin [bleeding: 6% vs. 30% in 1 retrospective cohort ( P = 0.1); composite death or major hemocompatibility-related events: 12.5% vs. 43% at 2-year follow-up ( P = 0.087)]. Dabigatran, a direct thrombin (factor IIa) inhibitor was associated with a 50% rate of pump thrombosis in a pilot randomized trial, leading to early termination. Significant heterogeneity in patient selection, regimens, and study design limits definitive conclusions. Anticoagulation management remains a major unmet need in LVAD therapy. Factor Xa inhibitor-based anticoagulation, particularly apixaban, may be associated with comparable thrombotic outcomes and lower bleeding risk versus warfarin in selected patients. Dabigatran carries high thrombotic risk and should be avoided. Adequately powered randomized trials are required to define optimal anticoagulation strategies in this population.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"190-197"},"PeriodicalIF":2.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148295066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluoropyrimidine Cardiotoxicity: Role of Uridine Triacetate and Pharmacogenomic Insights from a Case of 5-FU-Induced Cardiogenic Shock.","authors":"Simone Filomia, Marco G Del Buono, Gianluigi Saponara, Cristina Aurigemma, Riccardo Marano, Eleonora Moliterno, Giampaolo Tortora, Angelo Minucci, Lisa Salvatore, Paolo M Soave, Francesco Burzotta, Tommaso Sanna","doi":"10.1097/FJC.0000000000001853","DOIUrl":"10.1097/FJC.0000000000001853","url":null,"abstract":"<p><strong>Abstract: </strong>Fluoropyrimidines, including 5-fluorouracil and capecitabine, are widely used antimetabolite agents and remain central to the treatment of several solid tumors, particularly gastrointestinal malignancies. However, they are a well-established cause of chemotherapy-related cardiotoxicity. Although coronary vasospasm is the best recognized manifestation, fluoropyrimidine cardiotoxicity encompasses a broad clinical spectrum, ranging from chest pain and arrhythmias to acute heart failure, and, rarely, fulminant cardiogenic shock. This review discusses severe fluoropyrimidine-associated cardiotoxicity through the illustrative presentation of a young woman without previous cardiovascular disease who developed acute biventricular dysfunction and cardiogenic shock shortly after first exposure to FOLFIRINOX, requiring temporary mechanical circulatory support. Administration of uridine triacetate within the recommended therapeutic window was associated with rapid recovery of ventricular function. Cardiac magnetic resonance imaging demonstrated diffuse myocardial edema without late gadolinium enhancement, consistent with reversible toxic-inflammatory myocardial injury. Expanded genomic analysis identified dihydropyrimidine dehydrogenase and thymidylate synthase variants not detected by standard pretreatment pharmacogenetic screening. In this study we examine the pathophysiological mechanisms of fluoropyrimidine cardiotoxicity, the rationale for uridine triacetate in severe presentations, and the potential role of expanded pharmacogenomic profiling within a precision cardio-oncology framework.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"216-222"},"PeriodicalIF":2.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of EET-A Treatment on Cardiac Hypertrophy Induced by Isoproterenol in Sprague-Dawley Rats.","authors":"Sara A Helal, Samar H Gerges, Keshav Gopal, John R Falck, John R Ussher, Ayman O S El-Kadi","doi":"10.1097/FJC.0000000000001839","DOIUrl":"10.1097/FJC.0000000000001839","url":null,"abstract":"<p><strong>Abstract: </strong>Metabolites of arachidonic acid (AA) generated by cytochrome P450 (CYP) enzymes play significant roles in cardiac pathophysiology. Epoxyeicosatrienoic acids (EETs) exert vasodilatory, anti-inflammatory, and cardioprotective effects, but their rapid degradation limits therapeutic use. A metabolically stable analog, EET-A, was developed to mimic native 14,15-EET. The role of EET-A in cardiac hypertrophy and its interaction with CYP pathways remains unclear. This study investigated whether EET-A modulates cardiac hypertrophy, CYP enzyme expression, and AA metabolite formation in an isoproterenol (ISO)-induced model. Male Sprague-Dawley rats were administered ISO (1 mg/kg/d, i.p.) for 7 consecutive days to induce cardiac hypertrophy, with EET-A (10 mg/kg, i.p.) administered in parallel. Cardiac hypertrophy induction was confirmed, and the gene and protein levels of expression of cardiac CYP enzymes were assessed. Hydroxyeicosatetraenoic acids (HETEs) and EETs formation rates were measured using liquid chromatography-mass spectrometric analysis after incubating heart microsomes with AA. Concurrent administration of EET-A with ISO attenuated cardiac hypertrophy, as evidenced by reduced heart weight/body weight, heart weight/tibial length ratio, and the gene expression of β-myosin heavy chain compared with ISO alone. ISO significantly increased cardiac hypertrophic markers and altered CYP-mediated AA metabolism, including increased CYP1B1 expression, elevated mid-chain HETEs, and reduced EET formation rates. EET-A partially prevented these changes by suppressing CYP1B1 protein induction, decreasing 11-HETE formation, and restoring 8,9-EET levels. These findings indicate that EET-A attenuates ISO-induced cardiac hypertrophy and partially modulates CYP-dependent AA metabolism, conferring partial protection against β-adrenergic receptor agonist-induced cardiac remodeling.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"223-236"},"PeriodicalIF":2.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148329774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statins In Dialysis-Dependent End-Stage Renal Disease: Reconciling Discordant Evidence Through GRADE-Informed Appraisal and Evidence-to-Decision Framework.","authors":"Mahmoud Abdelnabi, Ramzi Ibrahim, Aya Elalfy, Reza Arsanjani","doi":"10.1097/FJC.0000000000001876","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001876","url":null,"abstract":"<p><p>In dialysis-dependent end-stage renal disease patients (ESRD), statin use remains an evidence-use dilemma: randomized controlled trials (RCTs) suggested limited benefit from statin initiation, whereas observational cohort studies reported lower mortality and cardiovascular events. This discordance creates uncertainty in prescribing, resource allocation, guideline interpretation, and shared decision-making. This analysis assessed whether this apparent conflict reflects true inconsistency, risk of bias, indirectness, or limitations in translating evidence into recommendations. Using narrative synthesis, GRADE-informed appraisal, and evidence-to-decision principles, an evidence-based, patient-centered approach is proposed based on the current available evidence.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple Antithrombotic Therapy for the Prevention of Left Ventricular Thrombus Following Anterior ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis.","authors":"Anastasios Apostolos, Vasileios Panoulas","doi":"10.1097/FJC.0000000000001872","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001872","url":null,"abstract":"<p><p>Left ventricular thrombus (LVT) is a serious complication of anterior ST-elevation myocardial infarction (STEMI). Despite guideline endorsement of prophylactic anticoagulation in selected high-risk patients, the supporting evidence remains of low certainty. Aim of our systematic review and meta-analysis is to evaluate the efficacy and safety of triple antithrombotic treatment (TAT) versus dual antiplatelet treatment (DAPT) alone for LVT prevention in patients with anterior STEMI treated with primary percutaneous coronary intervention (pPCI). Three electronic databases (EMBASE, MEDLINE, Cochrane Library) were systematically searched from inception to February 2026, following PRISMA 2020 guidelines. Eligible studies enrolled adult patients with anterior STEMI revascularised by pPCI, compared prophylactic TAT with DAPT alone, and reported LVT outcomes. Data were pooled as risk ratios (RR) with 95% confidence intervals (CI) using random-effects models. The primary outcome was LVT formation; secondary outcomes were major bleeding and systemic embolism. Six studies including 2,021 patients were analyzed. Pooled analysis demonstrated no statistically significant reduction in LVT formation with TAT (RR 0.54, 95% CI 0.21-1.40; p=0.21; I2=61%), whereas major bleeding risk was significantly increased (RR 2.69, 95% CI 1.40-5.19; p=0.003; I2=14%). A non-significant trend toward reduced systemic embolism was observed (RR 0.44, 95% CI 0.18-1.07; p=0.07; I2=0%). The addition of prophylactic anticoagulation to DAPT in patients with anterior STEMI treated with pPCI does not show a statistically significant reduction in LVT formation while significantly increasing major bleeding risk. These findings do not support routine prophylactic TAT in unselected patients with anterior STEMI.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular and Thromboembolic Risk With Upadacitinib in Spondyloarthritis and Inflammatory Bowel Disease: A Meta-Analysis of Randomized Controlled Trials.","authors":"Gabriela Stutz F Moreira, Lucas M Barbosa, Janaina Oliveira Lima","doi":"10.1097/FJC.0000000000001873","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001873","url":null,"abstract":"<p><p>Immune-mediated inflammatory diseases (IMIDs), including axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), Crohn's disease (CD), and ulcerative colitis (UC), share overlapping inflammatory pathways and frequently coexist, supporting the relevance of evaluating treatment safety across these conditions. Upadacitinib, a selective Janus kinase 1 inhibitor, is approved for multiple IMIDs; however, concerns regarding major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) have emerged based on class-related safety signals. We conducted systematic review and meta-analysis of randomized controlled trials to assess the risk of MACE and VTE associated with upadacitinib compared with placebo or active comparators in patients with spondyloarthritis (SpA) and inflammatory bowel disease (IBD). A systematic search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov identified eligible trials. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Eight RCTs comprising 4,433 patients were included, of whom 2,868 received upadacitinib. Across studies, MACE and VTE events were rare in both treatment and control groups. Upadacitinib was not associated with an increased risk of MACE (RR 0.35; 95% CI 0.05-2.19; p = 0.259) or VTE (RR 0.31; 95% CI 0.04-2.55; p = 0.279) in patients with SpA and IBD, with no observed heterogeneity (I2 = 0%). However, the low number of events resulted in wide confidence intervals and limited precision, precluding definitive conclusions regarding cardiovascular and thromboembolic safety. Larger randomized controlled trials and long-term real-world studies are needed to further evaluate these outcomes.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting IL-1 in SLE-Associated Recurrent Pericarditis: A Case Series and Review of Mechanistic Rationale.","authors":"Lindsay G Ott, Jordan Lindekens, Jenny Shah, Maria Salgado Guerrero, Jaya Batra, Anca Askanase, Ilan Richter, Elizabeth Park, Jason Liebowitz, Adam Mor, Daniel Oren, Gabriel Sayer, Nir Uriel, Dor Lotan","doi":"10.1097/FJC.0000000000001874","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001874","url":null,"abstract":"<p><p>Pericarditis is the most common cardiac manifestation of systemic lupus erythematosus (SLE), yet optimal management remains poorly defined. Glucocorticoids are frequently used but are associated with toxicity and increased recurrence risk. Interleukin-1 (IL-1) inhibition has demonstrated efficacy in recurrent pericarditis, though data in SLE-associated pericarditis is limited. In order to evaluate the clinical impact of IL-1 blockade on the treatment of SLE-associated recurrent pericarditis, we performed a retrospective case series of six patients with SLE-associated recurrent pericarditis treated with the IL-1 inhibitor rilonacept at a tertiary care cardio-rheumatology center. Clinical response, inflammatory markers, imaging findings, and use of concomitant therapies were assessed before and after IL-1 inhibition. Following initiation of rilonacept, all six patients achieved clinical improvement: three (50%) attained complete symptom resolution and three (50%) demonstrated partial symptomatic improvement. C-reactive protein normalized in all four patients with elevated baseline levels. Any post-treatment imaging, available in five of six patients (83.3%), demonstrated objective reduction in pericardial inflammation or effusion in all five. Use of concomitant therapies decreased substantially. IL-1 blockade with rilonacept was associated with clinical and imaging improvement and substantially reduced reliance on glucocorticoids and other anti-inflammatory agents in SLE-associated recurrent pericarditis. These findings support IL-1 inhibition as a targeted, steroid-sparing strategy in refractory disease and further prospective investigation.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empagliflozin Reduces Post-Myocardial Infarction Inflammation via BDH1/β-Hydroxybutyrate-Mediated NF-κB Modulation in Macrophages and the Heart.","authors":"Ji'e Yang, Ke Meng, Guohong Wu, Jiayu Liang, Jinyi Lin, Rong Huang, Jian Zhang, Dan Li, Xiangyong Kong, Hao Su, Feng Zhang, Junbo Ge","doi":"10.1097/FJC.0000000000001870","DOIUrl":"10.1097/FJC.0000000000001870","url":null,"abstract":"<p><p>Empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, demonstrates cardioprotective effects in heart failure, and recent trials suggest benefits in acute myocardial infarction (MI). However, the mechanisms underlying its efficacy, particularly its impact on the post-MI inflammatory response, are not fully elucidated. This study aimed to investigate whether EMPA modulates post-MI inflammation and to uncover the underlying molecular pathways. C57BL/6J mice undergoing MI were randomized to receive EMPA or saline for 7 days. EMPA treatment significantly improved survival, reduced fibrosis, and enhanced cardiac function. EMPA attenuated the systemic inflammatory response at day 1 post-MI, as evidenced by lower serum levels of IL-1β, IL-6, and CXCL-1. In the infarcted myocardium at day 1 post-MI, EMPA suppressed infiltration of neutrophils and pro-inflammatory macrophages while increasing anti-inflammatory macrophages. Mechanistically, EMPA upregulated the ketone body metabolic enzyme β-hydroxybutyrate dehydrogenase 1 (BDH1), increasing cardiac β-hydroxybutyrate (β-HB) levels, and subsequently inhibited NF-κB p65 phosphorylation. In immortalized bone marrow-derived macrophages, the anti-inflammatory effect of EMPA was mimicked by β-HB and abolished by Bdh1 knockdown, which was rescued by exogenous β-HB. In conclusion, EMPA attenuates maladaptive inflammation and confers cardioprotection after MI, potentially through a BDH1/β-HB/NF-κB pathway in macrophages. This ketone-mediated immunomodulatory axis, primarily defined in vitro, identifies a novel and potential​ pharmacological mechanism of SGLT2 inhibition in the context of post-MI inflammation.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ApoC-III Inhibition in Hypertriglyceridemia: From Triglyceride Lowering to Clinical Risk Modification.","authors":"Attilio Lauretti, Luigi Spadafora, Marco Bernardi, Antonio Di Matteo, Francesco Versaci","doi":"10.1097/FJC.0000000000001869","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001869","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Colchicine for the Treatment of Pericarditis in Patients with Chronic Kidney Disease.","authors":"Khaznah Saad A Alshammari, Sasha Pierre-Paul, Liriany Pimentel, Brittany Weber, Leo Buckley","doi":"10.1097/FJC.0000000000001866","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001866","url":null,"abstract":"<p><p>This retrospective multicenter cohort study compared the safety and efficacy of low- versus high-dose colchicine in adult patients with chronic kidney disease (CKD) treated for pericarditis between August 2015 and August 2024. CKD was identified using ICD codes and confirmed by an age- and sex-adjusted estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Patients with recurrent pericarditis or prior colchicine use before admission were excluded. Patients were categorized as receiving high-dose (≥0.6 mg/day) or low-dose (<0.6 mg/day) colchicine. The primary outcomes were colchicine-related adverse effects and a composite of dose reduction or discontinuation. Secondary outcomes included symptom improvement within 72 hours, recurrent pericarditis, and pericardial tamponade within 12 months. A total of 93 patients were included (53 high-dose and 40 low-dose). Idiopathic pericarditis was the most common etiology in both groups. End-stage kidney disease (57.5% vs. 15%) and dialysis (52.5% vs. 13%) were more common in the low-dose group. High-dose colchicine was associated with more gastrointestinal adverse events (39.6% vs. 12.5%, p=0.004), a higher rate of the composite outcome of dose reduction or discontinuation (41.5% vs. 20%, p=0.043), and more frequent dose reduction alone (30.2% vs. 7.5%, p=0.009), while discontinuation rates were similar. Symptom relief, recurrent pericarditis, and pericardial tamponade were comparable between groups. Initial colchicine doses of less than 0.6 mg daily were associated with improved tolerability in patients with CKD and pericarditis.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}